Analyst Price Targets — PTN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 14, 2026 11:54 am | — | Industrial Alliance Securities | $47.50 | $16.55 | TheFly | Palatin price target lowered to $47.50 from $50 at Alliance Global |
| December 12, 2025 10:02 am | — | Laidlaw | $60.00 | $24.67 | TheFly | Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals |
| December 3, 2025 12:04 pm | — | Industrial Alliance Securities | $50.00 | $19.63 | TheFly | Palatin initiated with a Buy at Alliance Global |
Latest News for PTN
StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It
Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndrome, generated $71.3 million of global revenue during the second quarter of 2026, including $51.0 million in the United States and representing a 19% sequential quarter increase in…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PTN.
U.S. House Trading
No House trades found for PTN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.